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Matrix metalloproteinases (MMPs) are known to be upregulated in inflammatory bowel disease (IBD) and other inflammatory
conditions, but while their involvement is clear, their role in many settings has yet to be determined. Studies of the involvement
of MMPs in IBD since 2006 have revealed an array of immune and stromal cells which release the proteases in response to
inflammatory cytokines and growth factors. Through digestion of the extracellular matrix and cleavage of bioactive proteins,
a huge diversity of roles have been revealed for the MMPs in IBD, where they have been shown to regulate epithelial barrier
function, immune response, angiogenesis, fibrosis, and wound healing. For this reason, MMPs have been recognised as potential
biomarkers for disease activity in IBD and inhibition remains a huge area of interest. This review describes new roles of MMPs in
the pathophysiology of IBD and suggests future directions for the development of treatment strategies in this condition.
1. Introduction
Inflammatory bowel disease (IBD) which includes both
ulcerative colitis (UC) and Crohn’s disease (CD) is a chronic
and relapsing autoimmune disease characterised by inflam-
mation of the gastrointestinal tract. The estimated mean
prevalence of IBD in western countries is 1 in 1,000 [1, 2] and
although data are less available for the developing world, inci-
dence of the disease is rising globally [3, 4]. Both idiopathic
forms of the disease share common symptoms of abdominal
pain, diarrhoea, rectal bleeding, and fever. Ulcerative colitis
is characterised by continuous inflammation involving the
rectum and colon which extends proximally. Crypt abscesses
from infiltration of neutrophils and ulceration of the mucosa
is observed. Crohn’s disease may affect any region of the
gastrointestinal tract intermittently with the terminal ileum
being the most common. The inflammatory process may
extend through the intestinal wall narrowing the intestinal
lumen and is histologically characterized by the formation of
granulomas, fibrosis, and fistulae [5, 6].
The humanmatrixmetalloproteinases (MMPs) are a fam-
ily of 24 zinc dependent endopeptidases.They are grouped by
domain structure and substrate preference into collagenases,
gelatinases, stromelysins, and membrane type MMPs (MT-
MMPs) [7]. The subgroups of MMPs have distinct structural
domains but all possess a conserved catalytic domain with
a Zn2+ at the active site and a prodomain which confers
latency. The family of proteases were first studied for their
ability to degrade the extracellular matrix and basement
membrane to facilitate cell migration, infiltration, and tissue
remodelling. As our understanding of MMPs has grown,
they have been recognised as key regulators of cell function
through their ability to cleave a vast range of cytokines,
chemokines, receptors, proteases, and adhesion molecules to
alter their function [8, 9]. MMPs are regulated at several
levels from transcription, translation, secretion, and activa-
tion. There is also a large list of physiological inhibitors of
MMPs which serve to regulate MMP activity and proteolysis.
The four tissue inhibitors of MMPs (TIMPs) are specific
inhibitors of MMPs that reversibly inhibit the MMPs in a 1 : 1
stoichiometric fashion.
These enzymes have long been linked with IBD and their
role in intestinal inflammation was reviewed by Medina and
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Radomski in 2006 [5]. Our current understanding of the
aetiology of IBD is that genetic susceptibilities in gut barrier
integrity and innate and adaptive immune response can lead
to an inappropriate inflammatory reaction in response to
bacteria in the gut or other environmental factors [10, 11]. It is
in this context that we review the recent evidence for the role
of MMPs in the disease.
2. Association between MMPs and IBD:
Enzymes Involved and Cellular Source
Most MMPs are transcriptionally upregulated in response
to proinflammatory cytokines, cell-cell, or cell-ECM interac-
tions [12]. The collagenases (MMP-1, -8, and -13), gelatinases
(MMP-2 and -9), stromelysins (MMP-3 and -10), matrilysin
(MMP-7), and macrophage elastase (MMP-12) are the most
studied in the context of IBD. The wide range of cellular
sources, which has been known to include epithelial cells,
mesenchymal cells, and leukocytes, has been reinforced in
recent studies. Myofibroblasts are now recognised as playing
an active role in intestinal inflammation and the pathogenesis
of IBD. These stromal cells have been shown to secrete
MMP-2 and, upon stimulation, MMP-1, -3 and -9 [13–15].
Human colonic epithelium was shown to produce increased
amounts of MMP-1, -3, -7, -9, -10, and -12 in IBD patients [16]
and mucosal biopsies from UC patients identified vascular
endothelial cells and infiltrating leukocytes as the major
sources of MMP-7 and -13 [17]. Infiltrating macrophages
were seen to be a major source of MMP-8, -9, and -10 in
human IBD and a mouse model of colitis [18, 19] and isolated
IgG plasma cells from IBD patients were shown to produce
high and sustained amounts of MMP-3 [20]. Neutrophils are
alsomajor contributors ofMMP-9 in intestinal inflammation
where it is stored in granules and can be released upon
stimulation [18, 21].
The range of cell types that secrete MMPs during intesti-
nal inflammation reflects their integral involvement in the
pathogenesis of IBD. Several studies from the previous
decade have suggested a role for MMPs in IBD by show-
ing their transcriptional upregulation and increased activity
during active inflammation in the gut. The evidence for
the involvement of MMPs in human IBD is unequivocal
and recent reports further describe instances, pattern of
expression, and cellular sources of the MMPs.
Transcripts or protein levels of MMP-1, -2, -3, -7, -9, -10,
-12, and -13 are demonstrated to be upregulated in inflamed
IBD mucosa or serum of IBD patients and MMP proteolytic
activity was increased in cells from inflamed IBD epithelium
[16, 22–25]. Gene expression profiling showed that MMP-
1 was upregulated in UC and CD and linked to HIF-1
mediated inflammation. MMP-3 and -7 were upregulated in
UC andMMP-7 was associated with genes known to regulate
angiogenesis [26, 27]. Other studies have focused on the
involvement of groups or individual MMPs in IBD ormodels
of colitis.
2.1. Gelatinases (MMP-2, -9). MMP-9 mucosal expression
and protein levels, as well as serum antigen levels were
significantly higher in UC patients compared to controls
and these levels corresponded to the severity of the disease.
Interestingly, these trends were not replicated in lymphocytic
colitis or collagenous colitis where MMP-9 does not seem to
contribute to the severity of the disease [28]. Gene expression
profiling combinedwith qPCR has shown the upregulation of
MMP-2 in paediatric CD [29]. This enzyme was also shown
to be upregulated in a rat TNBS-induced colitis model and
corresponded with the severity of the disease [30] which is in
agreementwith earlier studies [31, 32]. AmurineDSS induced
colitismodel showed increased gelatinasemRNA levels in the
colon [33]. Furthermore, patients with ischaemic colitis show
increased gelatinase expression in inflamed areas compared
with noninflamed areas or control patients implicating them
in inflammation [34] and gelatinase-double knockout mice
were protected from DSS, TNBS, or Salmonella typhimurium
induced colitis [35].
2.2. Stromelysins (MMP-3, -10). The expression of MMP-3
has been shown to be significantly upregulated in inflamed
areas of colons of IBD patients compared to uninflamed
areas implicating its involvement in the inflammatory process
[36]. In addition, increased expression of epithelial MMP-10
and stromal TIMP-3 has been found in both UC and CD
paediatric patients compared to non-IBD patients [37]. The
stromelysins were deemed to be the greatest contributors to
DSS induced colitis in one study and their inhibition with
siRNA or blocking of the signalling pathways leading to their
upregulation resulted in an amelioration of colitis [38].
2.3. Collagenases (MMP-1, -8, -13). MMP-1 has been shown
to be upregulated in ulcerated and inflamed areas of colon
mucosa of UC patients and its expression correlates with
severity of inflammation [39]. MMP-1 and TIMP-1 plasma
and colonic mRNA levels are increased in UC correlate
with disease severity [40]. Expression is also greater in the
inflamed areas of colons in UC patients and MMP-1/TIMP-1
ratio is a measure of inflammation [41]. A group studying the
Na+/H+ exchanger (NHE3) discovered that NHE3−/− mice
developed spontaneous colitis restricted to the mucosa of the
distal colon with a concomitant 15-fold increase in MMP-8
expression [42]. MMP-13 has also shown to be present in
the inflamed areas of colon in IBD patients but absent in
noninflamed colons or in acute diverticulitis and MMP-13
expression correlated with histological measures of disease
[43].
2.4. Macrophage Elastase (MMP-12). MMP-12 was also
shown to be upregulated in IBD patients as well as T-
cell mediated model of colitis and contribute to epithelial
degradation and MMP-12−/− mice were protected against
TNBS induced colitis [44]. Epithelial and stromal MMP-12
along with MMP-3 and -7 have been also upregulated in
pouch mucosa of paediatric onset UC, suggesting that the
expression of MMPs paediatric UC pouch in the long-term
shares characteristics with IBD [45].
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3. Genetic Basis of IBD: MMP Polymorphisms
Susceptibility to the development of IBD is associated with
polymorphisms in genes coding for elements of the immune
system or epithelial barrier. First degree relatives of IBD
patients have an increased relative risk of up to tenfold
compared with background population [46–48]. NOD2
(CARD15/IBD1) has been identified as a susceptibility gene
for CDwhich can affect host interaction with LPS and trigger
NF-𝜅B signalling [49–51]. Several large genome wide studies
have identified loci that are linked to IBD; 16q12 (IBD1),
12q13 (IBD2), 6p21 (IBD3), 14q11 (IBD4), 19p13 (IBD5),
5q31-q33 (IBD6), and Xq21.3 [52–57] and polymorphisms of
genes other than NOD2 have been identified as conferring
susceptibility including IL23R and ATG16L1 [58–60]. Given
the recognised involvement of MMPs in IBD and the strong
genetic component of the disease, several groups have investi-
gated the associations between knownMMP polymorphisms
and IBD phenotypes.
An extensive study of MMP-1, -2, -3, -7, -8, -9, -10,
-12, -13, and -14 and TIMP-1, -3, and -4 single nucleotide
polymorphisms (SNPs) in UC, carried out in a New Zealand
cohort, found that SNPs in MMP-3, MMP-8, MMP-10, and
MMP-14 were associated with the disease [61]. The study was
able to make associations with some of the SNPs and disease
phenotype but the associations made with UC were not
replicated in a Dutch cohort. Primary sclerosing cholangitis
(PSC) is a cholestatic liver disease characterised by chronic
inflammation and fibrosis. It is believed to share pathologies
with IBD and 50–80% of PSC patients also suffer from
IBD [62]. Polymorphisms of the MMP-3 gene have been
associated with PSC and with UC where the mechanisms are
likely to be the same but have yet to be determined [63–65].
An MMP-3 SNP has also been associated with increased risk
of stenosing behaviour in CD [66]. Preliminary studies have
shown associations between collagenous colitis and anMMP-
9 SNP but not MMP-1 or MMP-7 SNPs [67]. Two different
TIMP-1 SNPs were associated with increased susceptibility to
CD [66].
4. Role of Bacteria in IBD:
Interactions with MMPs
There is a body of evidence to suggest that gut microbes
are the key to the initiation and development of IBD. It
is likely that the disease is triggered by interaction of the
gut microflora with host defences following impaired barrier
function. Antibiotics or some probiotics have shown to be of
benefit in treating IBD [68, 69]. Further evidence for the role
of bacteria in triggering the disease is that gnotobiotic mice
do not develop colitis but it rapidly emerges when normal
luminal flora are reintroduced [70, 71] and that experimental
colitis can be induced in mice in response to adherent-
invasive E. coli, strains of Salmonella [72] or Helicobacter
[73, 74].
Much interest has been generated over the years in
specific species of bacteria which may be causative agents
for IBD. Mycobacterium avium paratuberculosis (MAP) has
sparked much recent debate regarding its involvement in
Crohn’s disease and is the subject of numerous reviews
and meta-analyses [75–84]. The subspecies is the causative
agent of Johne’s disease, an inflammatory disease mainly
in ruminants with similarities to CD such as diarrhoea,
leukocyte infiltration to the intestinal wall, and intestinal
lesions. Indeed, MAP has been shown to be present in a
higher percentage of IBD patients than healthy controls;
however, the associations have not proven to be conclusive
[77, 80]. MAP infection is associated with an upregulation
of MMPs in cattle and it upregulates MMPs in cultured
murine macrophages [85–87]. A recent study examined the
expression of MMPs in UC patients who tested positive for
MAPDNA but found it no different to patients withoutMAP
DNA [88]. In contrast to this, another group showed that
mice given oral MAP had increased colonic expression of
MMP-2, -9, -13, and -14 as well as TIMP-1 in response to the
bacteria [89].
A combination of the antibiotic minocycline and the
probiotic E. coli Nissle 1917 was shown to improve recovery
formDSS induced colitis in mice including improved ratio of
beneficial/harmful bacteria and reduced MMP-9 expression
[90]. However, no experiments were carried out to discern
the antibiotic effects of minocycline from itsMMP inhibitory
and immunomodulatory effects in reference to the protective
effect observed. A group studying Citrobacter rodentium-
induced colitis inmice found thatMMP-9was upregulated in
the model. While epithelial barrier integrity and histopatho-
logical observationswere unchanged betweenMMP-9−/− and
wild type mice, increased IL-17 expression was observed in
the MMP-9−/− mice. Interestingly, the gut microbiome was
altered inwild typemice following infection but not inMMP-
9−/− mice, implicating a role for MMP-9 in the depletion
of microbial diversity in the gut, after infection [91]. MMP-
7 can also modulate the gut microbiome where it has been
shown to cleave the inactive alpha-defensin, procryptdins, to
their active form [92]. Cryptdin-4 is mostly active against
noncommensal bacteria; however, its reduced form, which
is inactivated by MMP-7, demonstrates greater bacteriocidal
activity against commensal gut bacteria [93].
Interestingly, direct antibacterial effects for MMP-12 have
been demonstrated as it can disrupt bacterial cell membranes
in the macrophage phagosome [94].
5. Recent Pathways Regulating MMPs in IBD
MMPs are regulated at several levels from transcription to
enzyme activation. The interconnectedness of inflammatory
networks including activation of signal transduction path-
ways, where release of a cytokine can trigger an inflammatory
cascade, or indeed the protease web where activation of a
proenzyme can in turn lead to the activation of a host of
other enzymes and their targets, makes delineation difficult.
Despite decades of study, the place and role of MMPs in this
network is still under investigation and here we summarize
the recent studies of the place of MMPs in this network in
IBD (Figure 1).
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Figure 1: Recently described signalling pathways in the gut leading to the upregulation of MMPs in IBD or models of colitis. The various
mediators whose interaction with receptors on colonic epithelial cells, intestinal fibroblasts, myofibroblasts, and macrophages can trigger
signal transduction pathways leading to increased expression of MMPs or TIMPs are shown. PI3K𝛾 (phosphatidylinositol-3 kinase 𝛾),
NF-𝜅B (nuclear factor 𝜅B), TWEAK (TNF-related weak inducer of apoptosis), TGF-𝛽 (tissue growth factor 𝛽), cAMP (cyclic adenosine
monophosphate), PKA (protein kinase A), VIP (vasoactive intestinal peptide), VPAC1 (vasoactive intestinal peptide receptor 1), MAPKs
(mitogen activated protein kinases), ERK (extracellular signal-regulated kinase), PKC (protein kinase C), PKD (protein kinase D), and IL
(interleukin).
Some of these studies have shown new inducers ofMMPs
in IBD. IL-17A and IL-17F can increase secretion of MMP-
1 and -3 in subepithelial myofibroblasts and also enhance
the actions of IL-1𝛽 and TNF-𝛼 on these MMPs in a MAPK
mediated manner [95]. IL-21 was also shown to play a part
in the upregulation of MMP-1, -2, -3, and -9 in intestinal
fibroblasts without an increase in TIMPs [96]. TNF-like weak
inducer of apoptosis (TWEAK) is a member of the TNF-
family of cytokines that signals through its receptor, fibroblast
growth factor-inducible molecule 14 (Fn14). Inhibition of
the TWEAK pathway resulted in reduced severity of TNBS
induced colitis in mice resulting in reduced expression of
MMP-3, -9, -10, -12, and -13 along with other inflammatory
mediators [97].
Other recent studies have characterised various new sig-
nalling pathways involved in the transcriptional upregulation
of MMPs in intestinal inflammation. For example, inhibition
of Notch signalling reducesMMP-3 and -9 expression in DSS
induced colitis [98]. A recent study showed that inhibition of
PI3K𝛾 had anti-inflammatory effects in TNBS induced colitis
which resulted in increased Treg response and decreased NF-
𝜅B mediated expression of MMP-9 and other inflammatory
mediators [99]. VPAC1, a receptor for vasoactive intestinal
peptide (VIP), enhances DSS induced colitis through acti-
vation of PKA and increased MMP-9 expression, among
other mediators [100]. Colonic myofibroblasts were shown
to produce MMP-3 in response to bradykinin and TNF-
𝛼 through a pathway that involved activation of PKC and
ERK, establishing a critical role for the downstream PKD1
[15]. A study investigating the crosstalk between subepithelial
myofibroblasts and colonic epithelial cells found that the
myofibroblasts producedMMP-9 in response to the cytokines
TNF-𝛼, IL-1𝛽, and TGF-𝛽 but was inhibited by IFN-𝛾.
Interestingly, incubation of the myofibroblasts with media
containing the releasate of cytokine stimulated epithelial cells
resulted in an upregulation of MMP-9 which was mediated
by endothelin receptor A signalling [14]. TGF-𝛽1 was shown
to protect against TNBS induced colitis in mice through
upregulation of TIMP-3 in lamina propria mononuclear
cells. Knock-down of Smad7, the TGF-𝛽1 receptor antagonist,
resulted in increased TIMP-3 expression [101]. Chymase has
been shown to be a relevant activator of pro-MMP-9 in DSS
induced colitis [102]. In a study on the effects of mast cell
tryptase in IBD, MMP-3, -9, and -13 were downregulated in
DSS treated mast cell protease (MCP) 6/7−/− mice compared
to wild type DSS treated showing a regulation of theseMMPs
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Table 1: Recently described roles for MMPs in IBD.
MMP Role in IBD Reference
MMP-1 Prevention of fibrosis [145]
MMP-2 Generation of antiangiogenic factors, maintenance of epithelial barrier function,and prevention of fibrosis [119, 135, 145]
MMP-3 Generation of endostatin [118]
MMP-7 𝛼-defensin activation, chemokine expression, wound healing, and generation ofendostatin [105, 106, 118]
MMP-8 Neutrophil infiltration [18]
MMP-9
Chemokine expression, neutrophil infiltration, generation of anti-angiogenic
factors, VEGF-A processing, decreased goblet cell differentiation, and prevention of
fibrosis
[18, 107, 118, 119, 125, 134, 145]
MMP-10 Wound healing, [19]
MMP-13 Activation of TNF-𝛼 and generation of endostatin [111, 118]
MMP-20 Generation of endostatin [118]
by the proteases [103]. All these studies contribute to our
understanding of the signalling pathways involved in MMP
regulation in IBD.
6. New Evidence for Functions of
MMPs in IBD
As stated previously, the view of MMPs as simple ECM
proteases is vastly oversimplified. MMPs can activate or
inhibit a wide range of cytokines, chemokines, receptors,
adhesion molecules and signalling molecules in order to
regulate local inflammation in the gut and new roles are being
discovered continually (Figure 2). Here we review the recent
literature concerningMMP action in intestinal inflammation
beyond ECMdegradation. A summary is provided in Table 1.
6.1. MMPs in the Immune Response. The 𝛼-defensins, which
modulate IL-1𝛽, are cleaved and activated by MMP-7 [104].
MMP-7−/− mice were more susceptible to DSS induced
colitis. MMP-7 is postulated to reduce IL-1𝛽 release through
activation of 𝛼-defensins [105]. Another study highlights
the dual effect of the protease in colitis where it mediates
both tissue injury and also healing in DSS induced colitis.
MMP-7−/− mice had a lowermortality rate and the increased
inflammation in the wild type animals was ascribed to
increased neutrophil migration through increased expres-
sion of the chemokines KC and MIP-2 [106]. Transgenic
mice overexpressing epithelial MMP-9 developed worse DSS
and ST induced colitis which correlated with an increased
expression of KC [107]. An interesting recent study described
how MMP-10−/− mice developed a more severe colitis in
response toDSS and thatMMP-10 derived frommacrophages
was required for gut healing. Although the mechanisms of
this protection were not described, depleted macrophage
numbers in theMMP-10−/− micemayhave prevented colonic
healing [19]. Proline-glycine-proline (PGP) is a product
of collagen breakdown by propyl endopeptidase (PE) and
MMPs and is known to be a chemoattractant for neutrophils
[108]. It was recently demonstrated that this is a novel
mechanism for MMP induced neutrophil infiltration in
IBD where MMP-8, -9, and PE were upregulated in the
inflamed intestines of IBD patients and in mice with DSS
induced colitis. Generation of these enzymes resulted in PGP
and increased infiltration of neutrophils. PGP neutralisation
resulted in decreased neutrophil infiltration and lessened the
severity of the colitis [18].
TNF-𝛼 is a proinflammatory cytokine whose levels are
increased in the blood, colonic mucosa, and stools of IBD
patients. It contributes to the pathogenesis of the disease
by increasing inflammation through MAPK and NF-𝜅B
activation, increasing cell proliferation and altering epithelial
barrier permeability [109]. Anti-TNF therapy has been a
major breakthrough in recent years for the treatment ofmod-
erate to severe CD andUC refractory to traditional therapies.
Upon synthesis, homotrimeric TNF-𝛼 migrates to the cell
membranewhere it is cleaved into the soluble and biologically
active form. Until recently, TACE/ADAM17 was believed to
be the only relevant in vivo activator of TNF-𝛼 [110]; however,
MMP-13 has now been demonstrated to perform the same
function. Vandenbroucke et al. discovered that the observed
effects of MMP-13 on epithelial integrity in DSS induced
colitis, such as mucus depletion, intestinal inflammation,
and loss of tight junction function were mediated through
activation of TNF-𝛼 [111]. The significance of this discovery
in development of a therapy will remain to be seen.
6.2. MMPs in Angiogenesis. Angiogenesis is now believed to
play a major role in the process of chronic inflammation
and has been suggested to contribute to the pathology of
IBD. Early cytokine, chemokine, and growth factor release
facilitate the process which promotes increased leucocyte
infiltration. The understanding of angiogenesis in IBD was
summarised previously [112]; here we limit ourselves to the
more recent studies where MMPs are implicated.
Endothelial cell-produced MMP-1, -3, and -9 are upregu-
lated in human IBD and experimental colitis. These enzymes
are potentially involved in different aspects of angiogenesis.
MMPs could have dual roles in angiogenesis acting as proan-
giogenic mediators during tissue remodelling and then as
antiangiogenic mediators through generation of angiostatin
preventing vessel maturation. At a simplified level, MMPs




























Figure 2: Recently described functions for MMPs in IBD. A summary of some of the roles of MMPs in IBD is shown including regulation of
epithelial barrier throughMUC2 expression and activation of immune response through cleavage of procryptdins, chemokines, and cytokines.
MMPs also have a role to play in angiogenesis through allowing migration of endothelial cells and alteration of VEGF but also release of
endostatin and angiostatin. MUC2 (mucin 2), KC (CXCL1), MIP-2 (macrophage inflammatory protein 2), ZO-1 (zona occludens protein 1),
VEGF (vascular endothelial growth factor), and PGP (proline-glycine-proline).
facilitate angiogenesis through remodelling of the ECM, per-
mitting incorporation of migrating endothelial cells which
then form new vessels [113]. While this may be accurate,
regulation of angiogenic factors in the gut by MMPs is also
likely to contribute. It is known thatMMPs can release bound
forms of VEGF-A from the ECM, cell membrane, heparin
affinity regulatory peptide (HARP), and connective tissue
growth factor (CTGF), although the functional relevance of
this has been assessed in cancer models and not in IBD
[8]. MMP-1 and -3 can cleave heparin-sulfate proteoglycan
in endothelial cells to release basic fibroblast growth factor
(bFGF) [114] and transforming growth factor-𝛽 (TGF-𝛽) can
also be released and activated by MMPs [115–117]. Further
evidence for the roles of MMPs in angiogenesis is reviewed
by Rodŕıguez et al. [8].
Cleavage of collagen XVIII and plasminogen by several
MMPs can generate endostatin and angiostatin, respectively,
which are both antiangiogenic factors [118]. These antian-
giogenic factor levels were upregulated in a rat model of
UC. Administration of mesalamine was able to restore the
proangiogenic balance by inhibiting gelatinases and thus
generation of these fragments [119].
Others argue that increasing VEGF can lead to excessive
and pathological angiogenesis in IBD [120–122] and that
angiogenesis blockade may even be viable as a therapeutic
strategy for reducing disease severity in IBD [123]. In this
context, the increasing levels of MMP-9 lead to an increased
endostatin concentration and treatment with endostatin in
MMP-9−/− mice can reduce the severity of colitis [124]
indicating a protective role for the enzyme. The ability of
MMP-9 to release bound VEGF-A and alter its angiogenic
outcome [125, 126] was not assessed in the context of IBD
in the studies described; however, serum MMP-9 levels were
found to correlate with serum VEGF in CD but not UC
patients [127].The studies of the regulation of angiogenesis by
MMPs in IBD are limited in scope but provide evidence that
many of the discoveries made in cancer and other diseases
would also hold true for IBD. The net contribution of the
MMPs will depend on the microenvironment and thus the
generation of pro- or antiangiogenic factors.
6.3. MMPs and Epithelial Barrier Function. Epithelial barrier
integrity is essential in maintaining intestinal homeostasis.
Infiltration of luminal contents into the lamina propria
triggers a local inflammatory response leading to release of
proinflammatory mediators, release of MMPs, and further
epithelial degradation and inflammation. Indeed, leaking
of bacteria or alarmins into the bloodstream can trigger a
systemic response, sepsis, or multiorgan failure [128]. MMPs
have been implicated in modulation of the epithelial barrier
elsewhere in the body [129–131] and owing to its importance
in intestinal inflammation, also in the gut, as discussed below.
When investigating the effect of MMP-9 on the colonic
epithelial barrier in a model of colitis, it was found that
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MMP-9−/− mice had increased goblet cell numbers and
increased MUC2 expression. Overexpression of MMP-9
resulted in a decrease in goblet cell differentiation [107] and
thus decreased MUC2 expression. This reduction of MUC2
expression reduces the protective mucin barrier and was
shown to affect the adherence of Salmonella typhimurium
[132]. The tight junction protein claudin-1, which has been
previously implicated in colitis associated cancer (CAC)
[133], was shown to be involved in epithelial homeostasis.
Upregulation of claudin-1 following DSS induced colitis
results in an upregulation of MMP-9 which triggered Notch
signalling resulting in decreased MUC2 expression through
decreased goblet cell differentiation [134]. It was also shown
that the gelatinases play opposing roles in intestinal inflam-
mation where MMP-9 can potentiate colitis but MMP-2
participates in maintaining epithelial barrier function to
prevent the initiation of colitis [135].MMP-13 indirectly regu-
lates epithelial barrier function through activation of TNF-𝛼.
Activation of the cytokine increases intestinal epithelial per-
meability by mediating the endocytosis of the tight junction
protein ZO-1 and reducingMUC2 expression, effects that are
absent in MMP-13−/− mice [111].
In a DSS induced model of chronic colitis described
previously, wild type animals recovered more quickly and
completely from the colitis than MMP-7−/− animals which
may be due to decreased neutrophil infiltration to themucosa
[106]. MMP-7 was shown to be hugely upregulated in an
intestinal epithelial wound healing model and resulted in
faster resolution of the wound. Under inflammatory condi-
tions, simulated by addition of TNF-𝛼 and IL-1𝛽, the expres-
sion levels were increased further which delayed wound
healing [136]. This observation is likely applicable to many
of the MMPs, where physiological roles contribute to the
pathology of IBD under inflammatory conditions. Another
study showed the ability of MMP-7 to cleave galectin-3 and
to reverse its wound healing abilities [137]. The contribution
of this effect in vivo is undetermined but adds a further layer
of complexity.
6.4. MMPs in Intestinal Inflammation-Induced Fibrosis.
Fibrosis is a pathological accumulation of ECMwhich occurs
in the intestine as a consequence of IBD and has been recently
reviewed [138]. MMP expression, and the balance between
their levels and those of the TIMPs or other inhibitors, is
crucial for normal ECM homeostasis. A disruption of this
balance may promote fibrosis in the intestine. Despite ther-
apeutic advances in IBD, none prevent or reverse established
strictures. In UC, fibrosis will normally affect the mucosa
and submucosa whereas in CD, transmural thickening can
lead to stricture and require surgery [139]. In humans, TGF-
𝛽/Smad pathway seems to be a major contributor to fibrosis
in the gut where it can inhibit MMPs and increase the
production of TIMPs in mucosa overlaying strictures and in
culturedmyofibroblasts [96, 140]We have also found that the
TGF-𝛽/ALK5/Smad pathway participates in the pathogenesis
of experimental intestinal fibrosis. Indeed, upregulation of
ALK5 and TIMP-1, phosphorylation of Smad2 and Smad3
proteins, and increased intestinal wall collagen deposition
were found in anaerobic bacteria- and TNBS-induced colitis
[141]. In addition, the antifibrotic effects of glutamine in
TNBS induced colitis was partly attributed to abrogation of
the overexpression of TGF-𝛽, phosphorylated Smad3, and
TIMP-1 [142].
IL-13 is also said to play a role in fibrosis elsewhere in
the body partly through regulation of MMP-1 and TIMP-1
expression [143, 144]. A recent study showed that the cytokine
can inhibit expression of MMP-1, -2, and -9 in cultured
fibroblasts and that MMP-2 synthesis is not coordinately
upregulated along with that of collagen in fibrotic CD colons
[145]. In a DSS model of chronic colitis, the increased
expression of gelatinases was said to protect against fibrosis
through collagen degradation which is another protective
role for these enzymes [33].
6.5. MMPs in Colitis Associated Cancer. Chronic inflamma-
tion plays a critical role in gastrointestinal carcinogenesis.
As examples, chronic hepatitis, Barrett’s oesophagus and
IBD. Indeed, patients suffering from IBD are at higher risk
for developing colonic neoplasia than normal population,
particularly those with extensive colorectal inflammation
(pancolitis) which continues for longer periods of time [146].
Indeed, colorectal cancer accounts for one sixth of all UC-
related deaths [147]. The involvement of MMPs in colorectal
cancer and metastasis has been extensively studied [148]. We
have also found that MMP-9 upregulation is an early event
in the adenoma-carcinoma sequence and, therefore, MMP-9
might be amolecularmarker for early colorectal carcinogene-
sis [149]. However, colitis-associated colorectal cancer (CAC)
does not follow an adenoma-carcinoma sequence which is
initially associatedwith genomic instability and the concomi-
tant loss of key tumour suppressor genes. In contrast, CAC
shows an inflammation—dysplasia—carcinoma sequence, in
which a p53 mutation plays a key role in the early stage and
later the APC function is diminished [150].The p53 functions
as tumour suppressor; therefore, the loss or mutation of p53
could lead to neoplasia formation.
A summary of the role of MMPs in CAC is provided in
Figure 3. It is interesting to note that while colitis is mediated
by MMP-9, the same enzyme may play a protective role in
CAC. In fact, MMP-9 could play dual roles in CAC. It has
been shown that MMP-9−/− mice are more susceptible to
CAC than wild type mice and the protective effect of MMP-
9 is believed to be mediated through Notch-1 activation
and a subsequent decrease in 𝛽-catenin [151]. The same
group further investigated these effects and concluded that
the upregulation of MMP-9 in colitis leads to activation of
Notch-1, increased p53 expression leading to increased levels
of p21Waf/Cip1, and members of the Bax family proteins to
resulting in cell cycle arrest and apoptosis [152].
In contrast to the protective effects of MMP-9, a mouse
model of CAC found that activation of neutrophils by
the chemokine CXCL2 induced MMP-9 expression which
promoted neovascularization and possibly drove CAC [153].
Where integrin linked kinase (ILK) has been implicated in
carcinogenesis, ILK-intestinal epithelial cell knockout mice
showed reduced tumour growth and MMP-9 expression in


























Figure 3: MMPs in colitis associated cancer. A summary of the reported involvement of MMPs in colitis associated cancer (CAC) including
the dual roles of MMP-9 where it increases apoptosis and cell cycle arrest through notch cleavage and activation of p53 but also promotes
tumour growth, partially through activation of vascular endothelial growth factor (VEGF). MMP-7 is upregulated in UC associated dysplasia
and MMP-2 and -3 have also been reported to increase tumour growth. MMP-10 from macrophages is believed to inhibit colitis associated
cancer based on a knock-out mouse study.
experimentally induced CAC [154]. In addition, it has been
also shown that infliximab, an anti-TNF-alpha antibody,
could prevent CAC in DSS-induced colitis, an effect which
was accompanied by the reduction of MMP-9 and MMP-11
levels [155]. Similar results were observed when omeprazole
exerted a proapoptotic effect in amodel of CAC and inhibited
MMP-9 and -11 and MT1-MMP [156] and celecoxib reduced
gelatinase colon levels in models of CAC [157].
Examination of human UC biopsy samples revealed
that there was a direct correlation between the expression
of MMP-7 and the grade of UC-associated dysplasia or
carcinoma [158]. Further study is required to uncover the
precise role of the protease in the progression of the disease.
On the other hand, MMP-10 seems to play a protective role
fromCAC development as it has been found thatMMP-10−/−
mice had significantly worse inflammatory scores and also
higher propensity for development of dysplastic lesions after
DSS exposure [19]. More research is required to discover the
expression patterns of specific MMPs at the various stages
of CAC, to reveal the roles that the enzymes play and the
net contribution to tumorigenesis. This may then facilitate
successful targeting of specific enzymes as a treatment.
7. MMP Inhibition
Failure of MMP inhibitors (MMPIs) in cancer trials led to
a major rethink of the potential of these compounds in the
clinic, but we can now reflect on how little was known about
the functions of the specific MMPs in a given setting and
the clinical effect of inhibition. Early phase I trials revealed
unexplained musculoskeletal pain and inflammation which
limited the dosage that could be administered. Phase II/III
trials examining efficacy, were met with further problems.
Owing to the fact that the MMPIs were cytostatic and
not cytotoxic, conventional measures of efficacy such as
reduction in tumour size were not appropriate. Chosen
endpoint measures such as reduction in serum biomarkers
were criticized for not necessarily reflecting any reduction
in tumour growth and also for being unable to demonstrate
MMP inhibition [159]. Ultimately, the trials failed to demon-
strate efficacy and several were abandoned. Many researchers
now agree that invasive or metastatic cancer may not have
been appropriate diseases to trial of the drugs and that
preclinical studies suggest the drugs may be more useful
in treating earlier stage cancers or inflammatory conditions
[160]. A review by Hu et al. covers the history and considers
the future for MMP inhibition in the treatment of cancer
and inflammation [12]. With continuous studies teasing the
physiological from the pathological roles of MMPs in the
setting of IBD, we are getting closer to being able to imagine
clinical use of an MMPI in IBD. Here we summarise some
of the reports of MMP inhibition in intestinal inflammation
since 2006 (Table 2).
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Table 2: Recently reportedMMP inhibitors inmodels of intestinal inflammation. NovelMMP inhibitors, plant extracts tested in IBDmodels,
and existing IBD therapies are included where MMP-9 expression or activity has been measured.
MMP inhibitor MMPs inhibited Model Reference
RO28-2653 MMP-2, -9 DSS (mouse) (acute) [163]
Ilomastat MMP-1 TNBS (rat) [173]
Minocycline MMP-2, -3, -9, -13 DSS or TNBS (mouse) [172]
Etiasa (mesalazine) MMP-2 TNBS (rat) [30]
Irsogladine maleate MMP-2 DSS (mouse) [209]
Infliximab MMP-1, -2, -3, -9, -13 Human CD (serum and biopsy) [174, 175]
CC-10004 MMP-3 Mononuclear cells from human CD [165]
Nitrate-barbiturates MMP-9 Cytokine stimulated Caco-2 cells [161]
Auraptene MMP-7, -2, -9 DSS (mouse) [180]
coumarin 4-methylesculetin MMP-9 TNBS (rat) [181]
Tris(methoxymethoxy)chalcone MMP-7 TNF-𝛼 stimulated HT-29 cells [182]
Curcumin MMP-3 Cultured colonic myofibroblasts from IBD patients [183]
Phenylpropanoid glycosides: teupolioside
and verbascoside MMP-2, -9 DNBS (rat) [184, 185]
Neovastat MMP-9 TNBS (rat) [188]
Αlpha-lipoic MMP-9 DSS (mouse) [210]
Cordyceps militaris MMP-3 and -9 DSS (mouse) [189]
Calcium (CaHPO4) MMP-9, -10, -13 HLA-B27 transgenic rat [190]
7.1. SyntheticMMP Inhibitors. Various studies have examined
the potential of novel small molecule inhibitors of MMPs
in animal models of colitis. Barbiturate-nitrate hybrids can
inhibit MMP-9 activity partly through their nitric oxide
mimetic properties [161]. NO mimetics may have the para-
doxical effect of reducingNO/iNOS activity through negative
feedback, therefore, reducing inflammation and associated
MMP-9 release. Our group has recently reviewed the com-
plex interactions of NO and MMP-9 and exploiting these
interactions may be therapeutically beneficial in IBD [162].
Integration of a nitrate group as an NO donor may be a
novel approach to enhancing efficacy and reducing side-
effects of small molecule MMP inhibitors. The benefits of
the MMPI RO28-2653 in the DSS model were attributed to
its gelatinase selectivity. In particular, ability to spare MMP-1
and -7 reduced the side-effects observedwith broad spectrum
inhibition and efficacy was comparable to that of doxycy-
cline [163]. Novel synthetic curcuminoid pyrazole derivatives
inhibit MMP-9 activity in TNF-𝛼 and IL-1𝛽 stimulated
Caco-2 cells [164]. Sequestration of MMP-2 by hydroxamate
beads can inhibit MMP-2 activity and prevented disruption
of the epithelial barrier in an in vitro model and is an
interesting approach to MMP inhibition at the membrane
[129]. The thalidomide analogue, CC-10004, was shown to
reduce TNF-𝛼 and MMP-3 levels from mononuclear cells
isolated from the lamina of CD patients [165].
Vitamin D has inherent immunomodulatory properties
and synthetic analogues reduce hypercalcaemia. One such
compound, ZK156979, has been shown to be effective in
preventing TNBS induced colitis [166] and was shown to
inhibit gelatinase activity in cultured peripheralmononuclear
cells from healthy and IBD patients [167]. ZK191784 is an
intestine specific vitaminD analoguewhich can exert an anti-
inflammatory effect without causing hypercalcaemia [168–
170]. This compound and calcitriol were tested in cultured
colon biopsies of healthy and IBD patients and were found
to reduce MMP-2, -3, and -9 levels as well as the adhesion
molecules ICAM-1 and MAdCAM-1 [171].
Several studies have tested known MMPIs in models of
human IBD or assessed the ability of therapeutics used in
IBD to inhibit MMPs. The tetracycline antibiotics have long
been known for their anti-inflammatory properties and for
their ability to inhibit MMP expression. Minocycline was
shown to reduced inflammation in DSS or TNBS models by
reducing the expression of iNOS, proinflammatory cytokines,
and MMP-2, -3, -9, and -13 [172] with greater benefit seen in
DSS induced colitis when it is combined with the probiotic
E. coli Nissle 1917 [90]. The first generation hydroxamate
MMPI ilomastat was shown to protect rats from TNBS
induced colitis by inhibiting MMP-1 expression in the colon
[173]. Slow release granules of mesalazine were able to
reduce MMP-2 expression and inflammation [30]. A novel
mechanism was described for 5-ASA in angiogenesis during
UC where inhibition of TNF-𝛼 and gelatinase levels, reduced
the levels of angiostatin and endostatin [119].
The effects of the clinically used infliximab on gelatinase
levels in CD patients were examined and found that MMP-
9 serum levels were consistently decreased following inflix-
imab treatments andMMP-9 expressing polymorphonuclear
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leukocytes were also reduced in biopsy samples [174]. MMP-
3 and -12 were decreased following 10 weeks of infliximab
treatment in CD patients that were responders to the treat-
ment [175]. Using mucosal explants of IBD and control
patients, infliximab was shown to downregulate MMP-1, -3,
and -9 levels as well as reducing their increase in response
to pokeweed mitogen in a genotype dependent manner
following analysis of TNF,MMP, and TIMP SNPs [176]. It has
also been shown that infliximab could reduce the incidence
of tumour development through reduction of MMP-9 and
-11 in DSS-induced colitis [155]. Treatment of CD patients
with anti-TNF therapy (infliximab or adalimumab) or with
corticosteroids and other immunosuppressives (methotrex-
ate or azathioprine) resulted in a decrease of epithelial MMP-
7 and stromal MMP-9 and -26 and TIMP-1 and -3 [177]. In
a similar study, the same group showed results in paediatric
IBD where glucocorticoid therapy reduced serum MMP-7,
TIMP-1, andMMP-7/TIMP-2 and anti-TNF therapy reduced
MMP-7 but to a lesser extent. Interestingly, MMP-8 and -9
levels were not statistically significantly altered [178]. A larger
study used microarrays to measure the mucosal expression
of 24 MMPs along with TIMPs, ADAM(T)s, and growth
factors. Most MMP expression was increased in IBD patients
with the exception ofMMP-28whichwas downregulated and
responders to infliximab had a gene expression and gelatinase
activity was restored to control levels following treatment
[179].
7.2. Natural Products. Research is increasing in the field of
natural products as medicines and many of these have been
directed towardsMMP inhibition in intestinal inflammation.
The coumarin, auraptene, is found in several citrus
fruits and has been shown to inhibit MMP-7 activity fol-
lowing DSS induced colitis [180]. The naturally occurring
coumarin, 4-methylesculetin, showed comparable effects to
sulphasalazine and prednisolone in TNBS induced coli-
tis where it was able to inhibit MMP-9 [181]. 2󸀠,4󸀠,6󸀠-
Tris (methoxymethoxy) chalcone (TMMC) protected against
TNBS induced colitis and was able to inhibit MMP-7 upreg-
ulation induced by TNF-𝛼 in HT-29 cells [182]. Curcumin
is a component of turmeric with known anti-inflammatory
properties and one group investigating its use in IBD showed
that it could reduce MMP-3 among other mediators in ex
vivo cultured colonic myofibroblasts from IBD patients [183].
PPGs and verbascoside were shown to reduce inflamma-
tion, pro-inflammatory signalling and gelatinase expression
in DNBS induced colitis [184, 185]. Neovastat, a product
found in shark cartilage, is a known inhibitor of MMPs
and angiogenesis and has undergone clinical trials for the
treatment of renal carcinoma and plaque psoriasis [186, 187].
More recently, this agent has shown to inhibit intestinal
inflammation in TNBS induced colitis through inhibition of
gelatinase expression [188].Cordycepsmilitaris is a traditional
medicine widely used in East Asia to treat inflammatory
conditions and has been shown to inhibit disease activity,
along with iNOS and MMP-3 and -9 expression in a DSS
induced model of colitis [189]. Calcium supplementation
has shown benefit in reducing epithelial permeability and
inflammation in the intestine through reduced expression of
MMP-9, -10, and -13 in HLA-B27 transgenic rat model of
colitis [190].
The pineal gland productmelatonin is a known scavenger
of free radicals and has anti-inflammatory effects in experi-
mental colitis [191]. In certain instances, NO and peroxyni-
trite can modulate MMP-9 expression and activity [162] and
it is likely that the antioxidant properties of melatonin could
reduce colon gelatinase expression in DNBS induced colitis
[192]. Further investigation shows that it can mediate NF-
𝜅B, STAT-3, IL-17, Cox-2, nuclear erythroid 2-related factor
2, connective tissue growth factor, and MMP-9 [193] and its
contribution to IBD has been summarised recently [194].
Endogenous fatty acids are known gelatinase inhibitors
[195] and polyunsaturated fatty acids were recently shown
to be anti-inflammatory in the gut through decreased Cox-
2 and MMP-9 expression [196]. Orally administered docosa-
hexaenoic acid had comparable efficacy to sulfasalazine in
DSS induced colitis but with stronger inhibition of MMP-3,
-10, and -13 [197].
8. MMPs as Biomarkers for IBD
The association of MMPs with IBD is now widely accepted.
MMP expression or protein levels are now a standard read-
out for inflammation in the experimental models described
previously.There is an unmet need for additional biomarkers
to assess the progression of the disease or identification of
flares without the need for invasive, time consuming, or
expensive imaging techniques. Here we review the recent
studies regarding the potential and usefulness of MMPs as
markers for inflammation in IBD.
Faecal MMP-9 levels were reported to correlate with the
overall Mayo and endoscopic scores, serum CRP, and faecal
calprotectin levels inUCpatients [198]. As a biomarker, faecal
MMP-9 also has potential in recognising severity of pouchitis
and, to a lesser extent, CD where correlation with the SES
(simple endoscopic score) CDwas not statistically significant
but overall correlations were better than calprotectin [199].
However, neither faecal calprotectin nor faecal MMP-9 can
differentiate between Clostridium difficile induced and a
natural relapse in IBD [200].
Serum MMP-9 correlates with disease activity in UC
and CD and levels were found to be higher in UC. As a
result, this may aid in differentiation between UC and CD
where serum MMP-9 was more effective than CRP levels
[127]. Neutrophil secreted MMP-9 is often complexed with
NGAL and circulating levels of NGAL or NGAL/MMP-
9 complex have been associated with breast cancer [21]
and kidney disease [201]. This complex has recently been
described as a potential biomarker for mucosal healing in
UC where infliximab reduced serum levels, predictive of
mucosal healing [202]. Immunohistochemical staining of
colonic biopsy samples for paediatric onset UC patients
showed that MMP-9 levels correlated with the histological
measures of inflammation but not with any other marker of
disease [203]. Urinary gelatinase levels have also been found
to be independent predictors of IBD in paediatric patients
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[204] andMMP-3 andMMP-9 serum levels were found to be
potentially useful diagnostics of disease activity in children
with UC [205].
A gene expression approachwas used to assess differences
between responders and nonresponders to corticosteroid
treatment in severe paediatric UC. MMP-8 was strongly
upregulated in nonresponders compared to those patients
who had responded to treatment. This effect was believed to
be due to the inhibitory effect of methylprednisolone on IL-8,
a known inducer of MMP-8 [206].
Microarrays were used to assess the potential of biomark-
ers in peripheral blood as diagnostic indicators for IBD.
MMP-9 was found to be upregulated in IBD patients which
corresponded to the combined epithelial and lamina expres-
sion in biopsy samples. MMP-9 was identified in this study
as one of the top 5 peripheral blood transcripts which could
be used in combination to diagnose UC or CD [207]. A
large study investigated useful and appropriate biomarkers
in IBD and their correlation with the Mayo score in UC
or with the ileocolonoscopy (ICO), computed tomography
enterography (CTE), or combined ICO-CTE score in CD
patients as measures of inflammation. The study concluded
that combined faecal calprotectin and serum MMP-9 best
predicted inflammation in UC and combination of faecal
calprotectin, serumMMP-9, and serum IL-22 best correlated
with ICO-CTE score in CD [208].
The expression pattern of the TIMPs oftenmirrors that of
the MMPs and so the level of inflammation. Several studies
have investigated the potential of alsomeasuring TIMP levels
as readouts of inflammation severity. MMP-1 and TIMP-
1 are well known to be upregulated in UC and colonic
expression was found to correlate with disease severity. The
fact that plasma levels of these proteins correlated well with
the mucosal expression was of potential clinical interest
[40]. The intestinal expression of MMPs and TIMPs in CD
patients was measured before and following immunosup-
pressive treatment and found that the histological score
correlated positively with neutrophil MMP-9, MMP-26, and
macrophage TIMP-1. Calprotectin levels followed a similar
trend to expression of stromal MMP-26, TIMP-1, and -3.
Crohn’s disease endoscopic index of severity (CDEIS) value
correlated positively with macrophage TIMP-1 and stromal
TIMP-3 and negatively with epithelial TIMP-3 which also
negatively correlated with C-reactive protein values (CRP)
[177]. The levels of MMPs and TIMPs were measured by
immunohistochemistry only, and neither serum nor plasma
levels were assesed. In paediatric IBD, serumMMP-7mirrors
the disease activity and, together with TIMP-1 expression, is a
measure of response to glucocorticoid therapy but to a lesser
extent, anti-TNF therapy [178].
9. Concluding Remarks
Following recognition of the limited understanding of the
MMPs in earlier trials, the field has grown enormously to
discover more roles for the proteases. The fact that the
expression and activity of the MMPs is upregulated in colitis
and IBD has been confirmed through numerous animal
model experiments and analysis of IBD patient biopsies.
This has led to significant research into the use of MMPs
as biomarkers for the severity of inflammation in the colon
where results appear promising.
More studies continue to identify the primary cellular
sources of the MMPs in the colon and triggers of their tran-
scriptional upregulation or activation. A definitive under-
standing of cell types and signals involved in MMP upreg-
ulating will allow us to target the pathologically upregulated
enzymes.
It is clear from the range of MMP substrates and
degradomic experiments that the functions of MMPs in
IBD go far beyond the simple digestion of ECM proteins.
In recent years, more and more studies highlight the role
of MMPs in regulation of the immune response through
activation or inhibition of cytokines and chemokines, for
example, the activation of TNF-𝛼 which is exciting given
the established role of this cytokine in the pathogenesis
of IBD [110]. MMPs have the ability to regulate both pro-
and antiangiogenic factors which may contribute to the
pathogenesis of IBD ormucosal healing.The proteases have a
similar role in epithelial homeostasis through control of tight
junction proteins, goblet cell differentiation and degradation
of ECM proteins. These studies are vital to understand the
contribution of specific MMPs to a range of processes that
make up IBD. However, the potential to therapeutically
exploit these discoveries raises several questions. Paramount
to the discussion of MMP inhibition is the potential knock
on effect of the inhibition. Blocking a single enzyme will
affect activation of other proteases and its considerable list of
substrates which is likely to disrupt physiological processes.
Delineating these activation pathways, completing substrate
lists, and understanding the contexts where upregulation of
the protease is pathological will remain relevant questions
before MMP inhibition becomes a therapeutic option in
the clinic. Therefore, while new functions emerge for the
MMPs, it will be crucial to understand the setting where
an MMP is promoting or inhibiting wound healing, pro-
or antiangiogenic, or inhibiting or amplifying the immune
response. As answers to these questions emerge, we can be
more confident that targeted inhibition of the MMPs could
be of benefit in treating IBD.
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vitamin D analog ZK191784 as an intestine-specific vitamin D
antagonist,” The FASEB Journal, vol. 20, no. 12, pp. 2171–2173,
2006.
[170] U. G. Strauch, F. Obermeier, N. Grunwald et al., “Calcitriol
analog ZK191784 ameliorates acute and chronic dextran sodium
sulfate-induced colitis bymodulation of intestinal dendritic cell
numbers and phenotype,” World Journal of Gastroenterology,
vol. 13, no. 48, pp. 6529–6537, 2007.
[171] M. Martinesi, S. Ambrosini, C. Treves et al., “Role of vitamin
D derivatives in intestinal tissue of patients with inflammatory
bowel diseases,” Journal of Crohn’s and Colitis, vol. 8, no. 9, pp.
1062–1071, 2014.
[172] T.-Y.Huang, H.-C. Chu, Y.-L. Lin et al., “Minocycline attenuates
experimental colitis inmice by blocking expression of inducible
nitric oxide synthase and matrix metalloproteinases,” Toxicol-
ogy and Applied Pharmacology, vol. 237, no. 1, pp. 69–82, 2009.
[173] Y.-D. Wang and W. Wang, “Protective effect of ilomastat on
trinitrobenzenesulfonic acid-induced ulcerative colitis in rats,”
World Journal of Gastroenterology, vol. 14, no. 37, pp. 5683–5688,
2008.
[174] Q. Gao, M. J. W. Meijer, U. G. Schlüter et al., “Infliximab
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